LANTERN PHARMA INC
NASDAQ: LTRN (Lantern Pharma Inc.)
Last update: 10 hours ago1.12
-0.97 (-46.41%)
| Previous Close | 2.09 |
| Open | 2.23 |
| Volume | 7,369,131 |
| Avg. Volume (3M) | 52,889 |
| Market Cap | 12,526,554 |
| Price / Book | 3.15 |
| 52 Weeks Range | |
| Earnings Date | 30 Mar 2026 |
| Diluted EPS (TTM) | -1.84 |
| Total Debt/Equity (MRQ) | 1.16% |
| Current Ratio (MRQ) | 4.86 |
| Operating Cash Flow (TTM) | -19.12 M |
| Levered Free Cash Flow (TTM) | -11.95 M |
| Return on Assets (TTM) | -43.68% |
| Return on Equity (TTM) | -75.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Lantern Pharma Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.63 |
|
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group’s growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 14.10% |
| % Held by Institutions | 21.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bios Capital Management, Lp | 31 Dec 2025 | 1,009,507 |
| Voss Capital, Lp | 31 Dec 2025 | 50,000 |
| Newedge Advisors, Llc | 31 Dec 2025 | 38,069 |
| Westside Investment Management, Inc. | 31 Dec 2025 | 35,900 |
| Horizon Kinetics Asset Management Llc | 31 Dec 2025 | 27,582 |
| Davenport & Co Llc | 31 Dec 2025 | 23,814 |
| Date | Type | Details |
|---|---|---|
| 20 Jan 2026 | Announcement | Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas |
| 12 Jan 2026 | Announcement | Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |